Accession Number:

ADA555241

Title:

Probiotic (VSL#3) for Gulf War Illness

Descriptive Note:

Annual rept. 8 Sep 2010-7 Sep 2011

Corporate Author:

WESTERN INST FOR BIOMEDICAL RESEARCH SALT LAKE CITY UT

Personal Author(s):

Report Date:

2011-10-01

Pagination or Media Count:

10.0

Abstract:

The overall objective of the study was to determine whether Bifidobacterium infantis 35624 Align will improve symptoms of GW illness. We have not started the study as yet. This is due to inability to get IND Investigational New Drug number for the probiotic, Bifidobacterium infantis 35624 Align . The manufactures of Bifidobacterium infantis 35624 Align , Procter Gamble could not provide the necessary manufacturing information to Food and Drug Administration FDA. We requested the Department of Defense to allow us to use another commonly used probiotic, VSL3. The Department of Defense contract has been modified to include this change. The Confidentiality Disclosure Agreement between VSL Pharmaceuticals and the Department of Veterans Affairs has been agreed.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE